The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2023 | NCI9673: nivolumab with or without ipilimumab in anal cancer
Juan Manuel O’Connor, MD, MSc, Instituto Alexander Fleming, Buenos Aires, Argentina, provides an overview of the NCI9673 (NCT02314169) of nivolumab with or without ipilimumab in patients with metastatic squamous cell carcinoma of the anal canal. Whilst overall survival had promising improvement, there was no significant difference in the progression-free survival in both arms. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
